ArticleJournal of translational medicine2025
Design, synthesis and verification of HPV16 and HPV18 multiple antigens peptides.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
backgroundsDue to lack of immunotherapy of cervical cancer, human papillomavirus (HPV) multiple antigen peptide (MAP) were constructed and verified to explore a new approach for cervical cancer immunotherapy.
methodsHPV16MAP and HPV18MAP were added to HLA-A2-positive PBMC to verify their immune effects via enzyme-linked immunospot (ELISPOT). Then, cytotoxic T lymphocytes (CTL) were induced and identified in vitro. ELISPOT detected the number of activated CTL stimulated by corresponding antigens. The killing effect of CTL on SiHa and HeLa cells was analyzed by CCK8 and apoptosis assay. The mouse model was subcutaneously injected with polypeptide and the corresponding peptides were added to lymphocytes for ELISPOT. CCK8 and flow cytometry were used to detect the growth of TC1 cells and U14/HPV18E6E7 cells after co-culture with lymphocytes.
resultsThe number of lymphocyte spotting format counting (SFU) stimulated by adding HPV16MAP and HPV18MAP was significantly higher. HPV16MAP and HPV18MAP could induce specific CTL and effectively kill cervical cancer cells in vitro. The tumors of mice injected with HPV16MAP and HPV18MAP were significantly reduced. The results of CCK8 suggested that HPV18MAP-specific CTL had a significantly greater inhibitory effect on U14/HPV18E6E7 proliferation. And apoptosis rate of HPV16MAP and HPV18MAP-specific CTL was significantly increased.
conclusionsHPV16 MAP and HPV18MAP have good immune effects and peptide-binding ability in vitro and vivo. They may be potential in cervical cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.